ALX Oncology (ALXO) Competitors

ALX Oncology (NASDAQ:ALXO) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Do analysts recommend ALXO or IMRX?

ALX Oncology currently has a consensus target price of $3.30, suggesting a potential upside of 399.55%. Immuneering has a consensus target price of $13.25, suggesting a potential upside of 311.49%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities analysts clearly believe ALX Oncology is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Does the media refer more to ALXO or IMRX?

In the previous week, ALX Oncology had 2 more articles in the media than Immuneering. MarketBeat recorded 7 mentions for ALX Oncology and 5 mentions for Immuneering. Immuneering's average media sentiment score of 1.27 beat ALX Oncology's score of -0.35 indicating that Immuneering is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immuneering	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation & earnings, ALXO or IMRX?

Immuneering has higher revenue and earnings than ALX Oncology. Immuneering is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$134.85M	-$2.47	-0.27
Immuneering	$320K	362.15	-$61.04M	-$1.96	-1.64

Which has more volatility and risk, ALXO or IMRX?

ALX Oncology has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.

Is ALXO or IMRX more profitable?

ALX Oncology's return on equity of -104.43% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-104.43%	-77.74%
Immuneering	N/A	-119.22%	-99.22%

Do institutionals & insiders hold more shares of ALXO or IMRX?

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by insiders. Comparatively, 22.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ALX Oncology beats Immuneering on 9 of the 14 factors compared between the two stocks.